Literature DB >> 11548229

Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action.

P Creamer1, M Sharif, E George, K Meadows, J Cushnaghan, M Shinmei, P Dieppe.   

Abstract

The objective of this study was to investigate mechanisms of action of intra-articular hyaluronic acid in osteoarthritis (OA) of the knee. Twelve patients with bilateral knee OA and synovial effusions entered a randomized, single-blind, blind observer study. Hyaluronic acid ("Hyalgan", Fidia SpA, Italy) or placebo were given by intra-articular injection weekly for 5 weeks. Assessments included clinical indices and imaging (magnetic resonance imaging (MRI) and 99m Tc bone scanning) before and after the course of injections. In addition, synovial fluid keratan sulfate (KS), chondroitin sulfate (CS) and C-propeptide of type II collagen (CPII) were measured. MRI and 99m Tc scanning showed no change in either treated or placebo knees over the 6-week study period. A fall in KS levels occurred in treated knees compared with placebo (Wilcoxon paired test, P = 0.1), although this did not reach significance perhaps due to small sample numbers). Ten out of 12 treated knees showed a fall in KS, compared with four out of 12 placebo knees. CS and CPII levels did not change significantly. Intra-articular injection of hyaluronic acid did not result in any improvement in the clinical indices compared to the placebo. In conclusion, assessment of cartilage markers may be of value when studying novel therapies in OA. MRI appearances remain remarkably stable over a 6-week period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 11548229     DOI: 10.1016/s1063-4584(05)80063-9

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  15 in total

Review 1.  Viscosupplementation for osteoarthritis: a primer for primary care physicians.

Authors:  M Carrington Reid
Journal:  Adv Ther       Date:  2013-11-08       Impact factor: 3.845

2.  Intra-articular hyaluronan treatment for osteoarthritis.

Authors:  E George
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

3.  Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment.

Authors:  D Cubukçu; F Ardiç; N Karabulut; O Topuz
Journal:  Clin Rheumatol       Date:  2004-12-14       Impact factor: 2.980

Review 4.  Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis.

Authors:  Jasmin Arrich; Franz Piribauer; Philipp Mad; Daniela Schmid; Klaus Klaushofer; Marcus Müllner
Journal:  CMAJ       Date:  2005-04-12       Impact factor: 8.262

Review 5.  Current pharmacological treatment of osteoarthritis.

Authors:  F A Wollheim
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications.

Authors:  David D Waddell
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes.

Authors:  Valentina Grishko; Min Xu; Renee Ho; Aaron Mates; Scott Watson; Jong T Kim; Glenn L Wilson; Albert W Pearsall
Journal:  J Biol Chem       Date:  2009-02-04       Impact factor: 5.157

Review 8.  Viscosupplementation for the treatment of osteoarthritis of the knee.

Authors:  N Bellamy; J Campbell; V Robinson; T Gee; R Bourne; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 9.  Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action.

Authors:  Larry W Moreland
Journal:  Arthritis Res Ther       Date:  2003-01-14       Impact factor: 5.156

Review 10.  The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review.

Authors:  R D Altman; A Manjoo; A Fierlinger; F Niazi; M Nicholls
Journal:  BMC Musculoskelet Disord       Date:  2015-10-26       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.